Immunotherapies that mobilize a patient’s own immune system to fight cancer have become a treatment pillar. These therapies, including CAR T-cell therapy, have performed well in cancers like leukemias and lymphomas, but the results have been less promising in solid tumors.
Curaleaf Sells Stock at C$6
Curaleaf Announces C$16 Million Underwritten Offering of Subordinate Voting Shares NEW YORK, Sept. 28, 2023 /CNW/ – Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”
September 28, 2023